(MedPage Today) — SAN ANTONIO — In a large phase III trial of adjuvant treatment for early-stage breast cancer, the investigational oral drug giredestrant reduced the risk of invasive disease recurrence by 30% versus standard endocrine therapy…
Source link : https://www.medpagetoday.com/meetingcoverage/sabcs/118944
Author :
Publish date : 2025-12-10 22:45:00
Copyright for syndicated content belongs to the linked Source.
